Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may improve CV outcomes in patients with diabetes undergoing cancer therapy. The ...

Phase 2 trial findings support empagliflozin use in patients without diabetes for calcium and uric acid stone prevention. Empagliflozin use can reduce the risk of calcium and uric acid kidney stones ...

SGLT2 inhibitor use might be renoprotective in patients with ADPKD, but could increase kidney volume. Dapagliflozin might help protect kidney function in patients with autosomal dominant polycystic ...

The most important feature in all of these initial cases is that the patients did not recognize they had ketoacidosis, which is typically associated with severe hyperglycemia. As a result, instead of ...